Icosavax, Inc. is a biopharmaceutical company. The Company uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on life-threatening respiratory diseases. Its VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens. Its pipeline includes vaccine candidates targeting viral causes of pneumonia. It is developing these candidates for older adults, a patient population with high unmet need. Its lead vaccine candidate, IVX-A12, is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV). It is also developing additional vaccine candidates as part of its strategy to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults, including influenza and SARS-CoV-2.
ICOSAVAX, INC. 
